Journal of the American Academy of Dermatology
-
Proteus syndrome is a rare overgrowth disorder that is generally progressive, but the natural history of the skin lesions is not known. ⋯ Skin lesions of Proteus syndrome may not appear until later infancy or early childhood, making it difficult to diagnose in young children.
-
Rituximab is a genetically engineered antibody directed against the CD20 antigen. Intravenous administration of rituximab has been used for the treatment of patients with low-, intermediate-, and high-grade B-cell non-Hodgkin's lymphomas and is a registered treatment modality for this indication. Treatment of primary cutaneous B-cell lymphoma (CBCL) with intralesionally or systemically administered rituximab has been described only in a few cases. ⋯ Rituximab therapy is a well-tolerated and effective treatment for primary CBCL. In comparison to intravenous administration, intralesional application of the drug allows the use of lower dosages. Intralesional therapy with rituximab deserves further investigation and comparison to systemic administration of the drug in controlled multicenter studies.